Skip to main content

Arbutus Biopharma Corp

corporate_fare Company Profile

Arbutus Biopharma Corp

ABUS·NASDAQ·Life Sciences·CIK 0001447028

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on infectious disease. The company is developing imdusiran (AB-729), a proprietary, GalNAc-conjugated, subcutaneously-delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, a proprietary oral PD-L1 inhibitor, both for the treatment of chronic hepatitis B (cHBV). Arbutus is involved in ongoing litigation against Pfizer Inc. and BioNTech SE for their use of its patented lipid nanoparticle (LNP) technology in their COVID-19 messenger ribonucleic acid interference (mRNA)-LNP vaccines. A claim construction ruling was issued in September 2025. On March 3, 2026, Arbutus, along with Genevant Sciences GmbH and its parent, entered into a settlement agreement with Moderna, Inc. and its affiliates to resolve all patent infringement litigation and patent revocation proceedings. Under this agreement, Moderna will make an aggregate $950.0 million noncontingent lump sum payment to Arbutus and Genevant on or before July 8, 2026. Moderna is also obligated to pay an additional aggregate contingent lump sum payment of $1.3 billion upon a ruling favorable to Arbutus and Genevant in a limited appeal related to 28 U.S.C. §1498. Arbutus is entitled to receive 20% of the noncontingent settlement payment, after deduction of litigation costs, under its license with Genevant. As of the date of this annual report, Arbutus owns approximately 16% of the outstanding common equity of Genevant. The company is evaluating a return of capital to shareholders in the third quarter of calendar year 2026, following receipt of its portion of the noncontingent settlement payment.

Arbutus Biopharma Corp (NASDAQ:ABUS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 26 items for ABUS at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Arbutus Biopharma Secures $950M Moderna Settlement, Reports Strong Q4/FY25 Results, and Advances HBV Program
  • Arbutus Secures Up to $2.25 Billion from Moderna Patent Settlement, Plans Shareholder Capital Return
  • Moderna to Pay Arbutus $950M in LNP Patent Settlement, Potential $1.3B More
  • Court Bars Moderna's Obviousness & Derivation Defenses in Patent Suit, Enablement to Trial
  • Court Bars Arbutus Biopharma's Doctrine of Equivalents Claims in Moderna Patent Suit

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$14.08M
Net Income
-$33.5M
Diluted EPS
-$0.17
Op. Cash Flow
-$39.64M
Free Cash Flow
-$39.64M
Operating Income
-$38.16M
Cash & Equivalents
$18.01M
Debt / Equity
0.00×
Net Margin
-237.9%
Shares Outstanding
192.53M sh
Source: 10-K · filed 2026-03-23 · accession 0001447028-26-000017
$3.98 -1.00% today
52-week range · as of 2026-11-10 $3.5 – $5.45
Market cap
$616.24M
Volume
3M (1.2× avg)
3-mo avg 2.6M
Live data · 2026-11-22 12:45 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ABUS - Filings & News (Page 2)

ABUS
Mar 23, 2026, 7:31 AM EDT
Filing Type: 8-K
Importance Score:
10
Price at Filing: $4.24
Real-time Price: $3.98 info
Change: -$0.260 (-6%) info
Market Cap: $616.237M info
ABUS
Mar 23, 2026, 7:30 AM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $4.24
Real-time Price: $3.98 info
Change: -$0.260 (-6%) info
Market Cap: $616.237M info
ABUS
Mar 03, 2026, 4:23 PM EST
Source: Wiseek News
Importance Score:
10
Price at Filing: $5.10
Real-time Price: $3.98 info
Change: -$1.11 (-22%) info
Market Cap: $616.237M info
ABUS
Feb 20, 2026, 4:01 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.27
Real-time Price: $3.98 info
Change: -$0.290 (-7%) info
Market Cap: $616.237M info
ABUS
Feb 06, 2026, 4:01 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.87
Real-time Price: $3.98 info
Change: +$0.110 (+3%) info
Market Cap: $616.237M info
ABUS
Jan 16, 2026, 7:41 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.06
Real-time Price: $3.98 info
Change: -$0.075 (-2%) info
Market Cap: $616.237M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets